Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792166 | 0.98 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL7614766 | 0.88 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL7614772 | 0.85 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL12272001 | 0.80 | MAPK9 (0.40) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL10094582 | 0.79 | MAPK9 (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL4973497 | 0.78 | L3MBTL1 (0.58) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL16815410 | 0.77 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL28239177 | 0.77 | GAA (0.43) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA | |
| SCHEMBL1914614 | 0.76 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL30388994 | 0.76 | HTT (0.44) | L3MBTL1SMN1; SMN2MAPK9MAPK10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877382-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-3619204-B1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| CN-113260616-B | Novel compounds for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-113272298-B | Compounds and compositions for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12215095-B2 | Compounds for the treatment of respiratory diseases | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-04 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2022-12-01 | — | — | US | disclosed |
| US-20220281846-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2022-09-08 | — | — | US | disclosed |
| US-5739143-A | Imidazole compounds and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0809499-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215095-B2 | Compounds for the treatment of respiratory diseases | LTB4R2, LTC4S, CCL11 | L3MBTL1 4113/4885SMN1; SMN2 3884/4885MAPK9 3993/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | L3MBTL1 76/4885SMN1; SMN2 605/4885MAPK9 1155/4885 |
| US-20220281846-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, CCL11, LTB4R2 | L3MBTL1 4367/4885SMN1; SMN2 3731/4885MAPK9 3911/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | L3MBTL1 76/4885SMN1; SMN2 605/4885MAPK9 1155/4885 |
| US-20220380343-A1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | LTC4S, LTB4R2, LTB4R | L3MBTL1 4117/4885SMN1; SMN2 3328/4885MAPK9 4435/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | L3MBTL1 76/4885SMN1; SMN2 605/4885MAPK9 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.